 The European Commission has designated Orphan Drug status to Avrobio Incs NASDAQ: AVRO AVR-RD-04, its gene therapy to treat cystinosis. AVR-RD-04 consists of the patients hematopoietic stem cells, genetically modified to express cystinosin, the protein deficient in cystinosis patients. 